| IMMUNOVIA |
IMMUNOVIA |
92%
|
For the year ended December 31, 2025, 100% of our development service revenue, 100% of our other revenue, and 92% of our product sales revenue came from Immunovia |
| PROTEOMEDIX |
PROTEOMEDIX |
92%
|
Proteomedix provides a range of services to life sciences customers referred to as "Development Services" |
| CAMBRIDGE |
CAMBRIDGE |
90%
|
3% of our remaining product sales revenue came from Cambridge |
| LABCORP |
LABCORP |
90%
|
73% of our product sales revenue came from LabCorp |
| ZENTRUM-FUR-LABORMEDIZI |
ZENTRUM-FUR-LABORMEDIZI |
90%
|
5% of our remaining product sales revenue came from Zentrum fur Labormedizi |
| ABT |
Abbott Laboratories |
72%
|
me of which possess substantially greater financial, selling, logistical and laboratory resources, more experience in dealing with third-party payors, and greater market penetration, purchasing power… |
| ABT |
Abbott Laboratories |
72%
|
Reciprocal relationship from ABT graph: Reciprocal relationship from ONCO graph: me of which possess substantially greater financial, selling, logistical and laboratory resources, more experience in … |
| MDXH |
MDxHealth SA |
72%
|
me of which possess substantially greater financial, selling, logistical and laboratory resources, more experience in dealing with third-party payors, and greater market penetration, purchasing power… |
| MDXH |
MDxHealth SA |
72%
|
Reciprocal relationship from MDXH graph: Reciprocal relationship from ONCO graph: Reciprocal relationship from MDXH graph: Reciprocal relationship from ONCO graph: me of which possess substantially g… |
| OPK |
OPKO Health, Inc. |
72%
|
Reciprocal relationship from OPK graph: Reciprocal relationship from ONCO graph: Reciprocal relationship from OPK graph: Reciprocal relationship from ONCO graph: Reciprocal relationship from OPK grap… |
| OPK |
OPKO Health, Inc. |
72%
|
me of which possess substantially greater financial, selling, logistical and laboratory resources, more experience in dealing with third-party payors, and greater market penetration, purchasing power… |
| TECH |
Bio-Techne Corporation |
72%
|
Reciprocal relationship from TECH graph: Reciprocal relationship from ONCO graph: Reciprocal relationship from TECH graph: Reciprocal relationship from ONCO graph: me of which possess substantially g… |
| TECH |
Bio-Techne Corporation |
72%
|
me of which possess substantially greater financial, selling, logistical and laboratory resources, more experience in dealing with third-party payors, and greater market penetration, purchasing power… |
| XYF |
X Financial |
72%
|
Reciprocal relationship from XYF graph: Reciprocal relationship from ONCO graph: Reciprocal relationship from XYF graph: Reciprocal relationship from ONCO graph: and results are available quickly. Lo… |
| XYF |
X Financial |
72%
|
and results are available quickly. Local diagnostic laboratories can integrate this multiparametric test into their current workflow because Proclarix assays use the enzyme-linked immunosorbent assay… |
| ALTOS-VENTURE-AG |
ALTOS-VENTURE-AG |
62%
|
e or in part, any of the economic consequences of ownership of the Exchange Shares or the Conversion Shares, or (iii) publicly disclose the intention to do any of the foregoing, whether any such tran… |
| AMERICA-HOLDINGS |
AMERICA-HOLDINGS |
62%
|
e or in part, any of the economic consequences of ownership of the Exchange Shares or the Conversion Shares, or (iii) publicly disclose the intention to do any of the foregoing, whether any such tran… |
| BLUE-WATER-BIOTECH-INC |
BLUE-WATER-BIOTECH-INC |
62%
|
ate of Delaware to change its corporate name from “Blue Water Biotech, Inc.” to “Onconetix, Inc.” In connection with each of the name changes, the Company also amended the Company’s bylaws to reflect… |
| BLUE-WATER-VACCINES-INC |
BLUE-WATER-VACCINES-INC |
62%
|
me and resources needed to continue pursuing commercialization of ENTADFI, and (ii) the Company’s cash runway and indebtedness, the Company abandoned commercialization of ENTADFI and the ENTADFI asse… |
| KEYSTONE-CAPITAL-PARTNERS-LLC |
KEYSTONE-CAPITAL-PARTNERS-LLC |
62%
|
the September Veru Note is paid in full; ● Any amounts owed on the September Veru Note, including but not limited to unpaid principal and accrued interest, will be paid in cash or, upon the mutual wr… |
| REALBOTIX-LLC |
REALBOTIX-LLC |
62%
|
grams, and accordingly, we now operate in one segment: commercial. The commercial segment was new in the second quarter of 2023 and is currently dedicated to the development and commercialization of … |
| REPORT-LABORATORY-CORPORATION |
REPORT-LABORATORY-CORPORATION |
62%
|
eries E Warrants at the Variable Price. Additionally, the Warrant Limited Waiver waived the right of the Series D Warrants and the Series E Warrants to receive a guaranteed cash payment in connection… |
| WARRANT-LIMITED |
WARRANT-LIMITED |
62%
|
eries E Warrants at the Variable Price. Additionally, the Warrant Limited Waiver waived the right of the Series D Warrants and the Series E Warrants to receive a guaranteed cash payment in connection… |
